B Cell News and Research

RSS

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

The Jeffrey Epstein VI Foundation, a science foundation based in New York City, has helped finance the first mathematical model of how human cancer cells evolve, and more specifically, how they evolve to become immune to inhibitor drug therapy, a popular alternative to chemotherapy.

10 Apr 2013

MD Anderson scientists demonstrate new way to restore tumor suppression

Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

A molecular signature index technology that can lead to better radiation therapy decisions for patients with cancer is being developed into a reliable radiosensitivity test by CvergenX, Inc., an advanced cancer diagnostics company.

10 Apr 2013

Elekta's Versa HD system accelerates radiation delivery to new levels

Featuring a revolutionary combination of speed and accuracy, Elekta's new Versa HD system will help clinicians at The Christie NHS Foundation Trust (Withington, Manchester) maximize the precision of therapeutic beams on the tumor target, while also accelerating radiation delivery to new levels.

From Elekta 10 Apr 2013

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri.

10 Apr 2013

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Researchers presented data today on ARQ 092, an AKT inhibitor in Phase 1 clinical development by ArQule, Inc. at the AACR Annual Meeting held in Washington, D.C., April 6-10, showing that this novel, oral agent inhibits the AKT pathway and has a manageable safety profile in an ongoing Phase 1 clinical trial.

10 Apr 2013

Findings could help develop new ways to predict risks of tobacco-associated cancers

Believe it or not, while researchers have explored which genes are mutated in each type of tobacco-associated cancer, until now no one had thought to look across these types for common genes that might predict patient outcomes. Results presented at the AACR Annual Meeting 2013 show that in lung and bladder cancers, genes related to the regulation of the cell cycle are associated with poor patient outcomes.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Multiple genes strongly contribute to risk for schizophrenia

Multiple genes contribute to risk for schizophrenia and appear to function in pathways related to transmission of signals in the brain and immunity, according to an international study led by Virginia Commonwealth University School of Pharmacy researchers.

10 Apr 2013

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

Scientists from UCLA's Fielding School of Public Health led by Julia Heck, an assistant researcher in the school's epidemiology department and a member of UCLA's Jonsson Comprehensive Cancer Center, have found a possible link between exposure to traffic-related air pollution and several childhood cancers.

10 Apr 2013

New immunotherapies are seldom developed for childhood cancer

More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.

9 Apr 2013

Researchers develop predictive biomarker to identify cancer patients who may respond to autophagy inhibitors

Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation.

9 Apr 2013

UCSB researchers examine role played by Rhs proteins in bacterial intercellular competition

There's an epic battle taking place that's not on the national radar: intercellular competition. While it's not an Olympic event, new research from UC Santa Barbara demonstrates that this microscopic rivalry can be just as fierce as humans going for the gold.

9 Apr 2013

Research: ACOT7 enzyme keeps neurons' fat levels under control

We're all fatheads. That is, our brain cells are packed with fat molecules, more of them than almost any other cell type. Still, if the brain cells' fat content gets too high, they'll be in trouble. In a recent study in mice, researchers at Johns Hopkins pinpointed an enzyme that keeps neurons' fat levels under control, and may be implicated in human neurological diseases.

9 Apr 2013

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

Genes for blood vessel growth in retina are "switched on" by SRF protein

Normal functioning of the eye depends on a proper supply of blood to the retina. Light entering the eye passes through the cornea, the lens, and the vitreous body before reaching the retina, where it stimulates the nerves.

9 Apr 2013

UT professor earns INNOVATOR Award for Cancer Prevention Research at AACR meeting 2013

A proposal to examine the cellular journey from normal skin, to precancerous lesion to skin cancer earned Kenneth Tsai, M.D., Ph.D., the Sixth Annual Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research at the AACR Annual Meeting 2013 in Washington, D.C., April 6-10.

9 Apr 2013

Transient electronics relieve pain, fight infection and dissolve harmlessly

Scientists today described key advances toward practical uses of a new genre of tiny, biocompatible electronic devices that could be implanted into the body to relieve pain or battle infection for a specific period of time, and then dissolve harmlessly.

9 Apr 2013

Nano-sized EVs play role in cancer growth and survival

The recent discovery of circulating "nano-sized extracellular vesicles" (EVs) carrying proteins and nucleic acids derived from brain tumors may lead to exciting new avenues for brain cancer diagnosis, monitoring, and treatment, according to a special article in the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

9 Apr 2013

B Cell News and Research

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

MD Anderson scientists demonstrate new way to restore tumor suppression

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

CvergenX to develop radiosensitivity test to better radiation therapy decisions for patients with cancer

Elekta's Versa HD system accelerates radiation delivery to new levels

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Researchers present data on ARQ 092 at 2013 AACR Annual Meeting

Findings could help develop new ways to predict risks of tobacco-associated cancers

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Multiple genes strongly contribute to risk for schizophrenia

Exposure to traffic-related air pollution associated with increases in rare childhood cancers

New immunotherapies are seldom developed for childhood cancer

Researchers develop predictive biomarker to identify cancer patients who may respond to autophagy inhibitors

UCSB researchers examine role played by Rhs proteins in bacterial intercellular competition

Research: ACOT7 enzyme keeps neurons' fat levels under control

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Genes for blood vessel growth in retina are "switched on" by SRF protein

UT professor earns INNOVATOR Award for Cancer Prevention Research at AACR meeting 2013

Transient electronics relieve pain, fight infection and dissolve harmlessly

Nano-sized EVs play role in cancer growth and survival

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News